Article Information
History
- November 23, 2021.
Article Versions
- You are currently viewing Version 1 of this article (November 23, 2021 - 07:01).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Hossein Faramarzi, M.D.1,
- Amirhossein Sahebkar, Pharm.D., Ph.D.2,3,
- Ahmad Hosseinpour, M.Sc.4,*,
- Vahid Khaloo, M.D.5,
- Parisa Chamanpara, Ph.D.6,
- Mohammad Reza Heydari, Pharm.D., Ph.D.7,
- Sajad Najafi, Ph.D.8,
- Fatemeh Fotoohi Khankahdany, M.Sc.4 and
- Ahmad Movahedpour, Ph.D.9
- 1Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
- 2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- 3Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- 4Shimi Teb Salamat Co., Shiraz, Iran
- 5Ali Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
- 6Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran
- 7Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
- 8Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 9Behbahan Faculty of Medical Sciences, Behbahan, Iran
- ↵*Correspondence to: Ahmad Hosseinpour,
M.Sc. in Nanomedicine, CEO, Shimi Teb Salamat Co., No.1, Ghiam St., Alley No.7, Dabaghi St., Shiraz, Iran. E-mail address: ahosseinpour3{at}gmail.com, Tel: +989171359457
Posted November 23, 2021.
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
